PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

London, UK, 24 March, 2022

PharmaVentures is pleased to announce that it acted as transaction advisor to Lausanne University Hospital (CHUV) and EPFL in Switzerland on their commercial terms related to the collaboration and licensing of their highly potent SARS-CoV-2 monoclonal antibodies to the newly founded biopharmaceutical company Aerium Therapeutics, based in Boston, MA, USA and Lausanne, Switzerland.

Aerium Therapeutics is focused on discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2. Its initial efforts are focused on two monoclonal antibodies that, in preclinical testing, have shown potent neutralisation of important COVID-19 Variants of Concern (VOCs), including Delta, Omicron and the recent Omicron subvariants BA.1, BA.1.1, BA.2, and is thus markedly more potent than all authorised or clinically advanced anti-SARS-CoV-2 mAbs. 

The company has recently emerged with substantial Series A financial backing by the founding investor Omega Funds with the participation of F-Prime Capital. Aerium was seeded and incubated by Omega Funds in 2021 and started in collaboration with its two scientific founders, Dr. Giuseppe Pantaleo (CHUV) and Dr. Didier Trono (EPFL) in Switzerland. Both scientists are applying their substantial expertise and research capabilities to discover new mAbs against SARS-CoV-2.

This follows the recent announcement that this novel antibody is one of the most powerful identified so far against all SARS-CoV-2 variants of concern. In addition to its antiviral properties, the antibody has been designed to provide protection to those patients most vulnerable.

Fintan Walton, Founder and CEO of PharmaVentures, said “We are delighted to have advised CHUV and EPFL on their commercial terms for this break-through research that has significant potential to protect those who are left as most vulnerable to COVID-19.”

Dr. Giuseppe Pantaleo, Professor of Medicine at the CHUV, Head of Immunology and Allergy Division said “Our collaboration with Aerium Therapeutics will be key in delivering these antibodies to the clinical stage, where they have the potential to play an important role in the control and the prevention of COVID-19, particularly in all those who are not protected by vaccination.”

– Ends –

For further information, please contact:

Lisa Holloway
Senior Marketing Manager
Phone: +44 (0) 1865 332700
lisa@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising Support
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, and fundraising)

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

About CHUV

Lausanne University Hospital is one of the five university hospitals in Switzerland, with Geneva, Bern, Basel and Zurich. With its 16 clinical and medico-technical departments and their numerous services, the CHUV is renowned for its academic achievements in health care, research, and teaching.

The CHUV is also a well-known center of medical education and research thanks to its collaboration with the Faculty of Biology and Medicine of the University of Lausanne and the Swiss Federal Institute of Technology in Lausanne (EPFL). Together, these institutions form a vast campus in the Lake Geneva region.

About EPFL

EPFL (www.epfl.ch), one of the two Swiss Federal Institutes of Technology, based in Lausanne, is Europe’s most cosmopolitan technical university with students, professors and staff from over 120 nations. A dynamic environment, open to Switzerland and the world, EPFL is centered on its three missions: teaching, research and technology transfer. EPFL works together with an extensive network of partners including other universities and institutes of technology, developing and emerging countries, secondary schools and colleges, industry and economy, political circles and the general public, to bring about real impact for society. 

PharmaVentures moves HQ to London to support its continued growth strategy

London, UK, 10 February 2022

PharmaVentures today announced it has moved its operational headquarters from Oxford to London as part of its continued strategic expansion. The company will retain its remaining operational and administrative functions at its new registered office in Oxford.

Dr Fintan Walton, Chief Executive and Founder of PharmaVentures said: “As a leading global transaction advisory firm, it makes sense that PharmaVentures moves its functional operations to one of world’s leading financial cities. We wanted a location that reflects PharmaVentures’ forward-thinking culture and enterprise. So, in the end London was the obvious choice.”

The new London Headquarters is close to Paddington Station, serving both Oxford and London’s Heathrow Airport, and making it extremely convenient for its global clients travelling to London. Located in the West End and in the newly developed and dynamic city campus called Paddington Central, the offices are just a short walk from London’s famous and quaint Little Venice where the Grand Union Canal meets Regent’s Canal.

The new London address is: One Kingdom Street, Fourth Floor, Paddington, London W2 6BD, United Kingdom.

The new Oxford and registered address is: Oxford House, Oxford Business Park South, Oxford OX4 2JY, United Kingdom.

– Ends –

For further information, please contact:

Lisa Holloway
Senior Marketing Manager
Phone: +44 (0) 1865 332700
lisa@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising Support
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, and fundraising)

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

PharmaVentures' London HQ
PharmaVentures’ new London HQ is at One Kingdom Street, Fourth Floor, Paddington, London W2 6BD, United Kingdom.

PharmaVentures and Shinhan Investment Corp sign Memorandum of Understanding to strengthen global collaboration for the Korean biopharma industry

Oxford, UK, 18 November 2021

PharmaVentures is delighted to announce it has signed a Memorandum of Understanding (MOU) with the leading Korean investment bank, Shinhan Investment Corp Group & Global Investment Banking Group (SHIC). This MOU was signed by Adrian Dawkes, Managing Director at PharmaVentures and Keun Soo Chung, SHIC GIB Group Head, during an event last week at Seoul Yeouido SHIC tower, Seoul, South Korea.

Through this MOU, PharmaVentures and Shinhan Investment Corp intend to collaborate closely to provide a much broader range of capabilities and services to both Korean biotech companies and global biopharma companies looking at the Korean biotech opportunity. This will allow better access for the pharma and biotech industry to the financial services provided by Shinhan Investment Corp and the corporate advisory services provided by PharmaVentures who have reach into the global markets.  The collaboration intends to give Korean companies better access to global markets, and for international companies to gain greater access to the Korean bio industry and its capital markets.

Adrian Dawkes, Managing Director at PharmaVentures said “We have been assisting many Korean biotech companies over the last 5 years and with our new collaboration with Shinhan Investment Corp we will be able to assist even more companies and bring the technology innovations of the Korean biotech sector to new audiences globally”.

SHIC GIB Group Head Keunsoo Chung said, “Starting with this MOU, SHIC will assist bio ventures to successfully enter the capital market and provide differentiated investment banking services to mid-to-large size pharma to succeed in global biopharma industry. This MOU provides groundwork to improve the quality of strategic consulting and financial services for Korean bio/healthcare companies to innovate the IPO and M&A domains”.

Fintan Walton, Founder and CEO of PharmaVentures, said PharmaVentures has a long and strong history in supporting our clients in their deal making activities. Our specialist knowledge and experience of the Korean emerging biopharmaceutical sector sets us apart from other transactions advisory firms. We have the expertise to connect the Korean and Western Biopharma industries and vice versa, enabling them to collaborate through licensing and M&A deals.”

South Korea is recognised as one of the leading nations for innovation, and Western pharmas are increasingly turning their attention to the rapidly expanding biotech sector there.  

Examples of PharmaVentures work with Korean clients include:

  • Advisor to IntoCell throughout the initiation, negotiation, and execution of this multi-target collaboration agreement with Cellectar read more
  • Advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting CXCR4 read more
  • Valuation advisor to Yuhan Corporation on its licensing of Lazertinib for NSCLC to Janssen read more

– Ends –

For further information, please contact:

Adrian Dawkes​
Managing Director
Phone: +44 (0) 7931 428487
adrian@pharmaventures.com

Luke Lee​
Associate
Phone: +44 (0) 7859 885177
luke@pharmaventures.com

Jessie You
Associate
Phone: +44 (0)7387 101283
jessie@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For nearly 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, and fundraising)

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

For more details, visit https://www.pharmaventures.com

Shinhan Investment Corporation

Shinhan Investment Corp (SHIC) is one of Korea’s leading securities brokerage and investment banking houses. Through merger with Shinhan Securities, SHIC set a solid platform to become an investment powerhouse with excellence in financial service advisory and execution. SHIC’s long-term objectives and determination lie in pursuing high capital efficiency and business diversification, achieving industry’s top client and employee satisfaction, sustaining profitable growth in the long-term and most importantly creating higher value for their shareholders.

This MOU was signed by Adrian Dawkes, Managing Director at PharmaVentures and Keun Soo Chung, SHIC GIB Group Head, at Seoul Yeouido SHIC tower, Seoul, South Korea.

PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio

Oxford, UK, 15 October 2021

PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio.

This follows the recent announcement that IntoCell has established a research collaboration partnership with Ab Studio to develop antibody drug conjugate (ADC) using IntoCell’s proprietary PMT payloads and Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker technology, and a novel internalizing antibody from Ab Studio.

Steve Waterman, Managing Director at PharmaVentures, said “We are pleased to have assisted IntoCell with forming another research and development collaboration, and we look forward to seeing the results of combining IntoCell’s OHPAS linker and PMT payload technologies with Ab Studio’s innovative approach to antibody discovery.

Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures has advised and supported IntoCell through the course of their discussion with Ab Studio for the research collaboration agreement. PharmaVentures hopes to continue the strong relationship with IntoCell in advising on their business development and licensing activities with our special insight accumulated over many years of supporting Korean biotech companies.”

– Ends –

For further information on Intocell’s opportunities, contact:

Stephen Waterman
Managing Director
PharmaVentures Ltd
stephen@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For nearly 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, and fundraising)

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

For more details, visit https://www.pharmaventures.com

About IntoCell, the OHPAS linker and PMT technology

IntoCell has developed a state-of-the-art linker technology comprising of a novel self-immolative group based on Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) chemistry that works with a wide variety of phenolic and non-phenolic payloads. The OPHAS linker was designed to accommodate a wide variety of functional groups and triggering groups. The OHPAS Linker can be triggered by methods that include enzymes (i.e., lysosomal), light, and pH. The resulting ADCs has been shown to be highly stable and have very fast payloads release profiles.

IntoCell has devised another ADC platform technology called Payload Modification Technology (PMT) in which temporary Modifying Group (MG) has been incorporated into traditional payloads. PMT has shown to improve therapeutic index of ADC with significant reduction of normal cell’s uptake, resulting in normal cells being minimally affected.

By utilizing PMT and OHPAS linker technology, IntoCell has successfully delivered a preclinical candidate in the B7-H3 ADC program. ITC-6146RO is the lead candidate that shows high and long-lived potency in a variety of murine xenograft and PDX models with good safety. IND-enabling studies of ITC-6146RO are planned in 2022.

For more information, please visit http://www.intocell.co.kr

PharmaVentures acts as advisor to Intocell on their ongoing collaboration agreement with Cellectar

Oxford, UK, 15 July 2021

PharmaVentures is pleased to announce that it is acting as advisor to Intocell on their ongoing collaboration agreement with Cellectar.

This follows the announcement that Cellectar and Intocell have expanded their collaboration using Intocell’s proprietary OHPAS linker and payload technologies to develop novel phospholipid ether drug conjugates (PDCs).

Steve Waterman, Managing Director at PharmaVentures, said “The collaboration with Cellectar has produced exciting preclinical results with multiple payloads, and the decision to advance these programmes into Investigational New Drug (IND) enabling studies is very encouraging.

We are looking forward to continuing to support Intocell with partnering of its Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker and its novel payloads that promise a wider therapeutic index over existing technology. Equally exciting is the progress with its pipeline of proprietary antibody drug conjugates (ADCs), the most advanced of which is its B7-H3 ADC. ”

Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures is pleased to have advised Intocell throughout the initiation, negotiation, and execution of this multi-target collaboration agreement with Cellectar. PharmaVentures has a long and strong history in supporting our clients in their deal making activities due to our considerable transactional insight of the healthcare sector.  Furthermore, our specialist knowledge and experience of the Korean emerging biopharmaceutical sector sets us apart from other transactions advisory firms.”

– Ends –

For further information on Intocell’s opportunities, contact:

Stephen Waterman
Managing Director
PharmaVentures Ltd
stephen@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For nearly 30 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, and fundraising)

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

For more details, visit https://www.pharmaventures.com

About IntoCell and the OHPAS linker 

IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate (ADC) platform technologies comprising scaffold moiety, ligands, toxins, linkers and conjugation methods. IntoCell has developed a novel self-immolative Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker that works with a wide variety of functional groups, triggering groups, and both phenolic and non-phenolic payloads. The resulting ADCs have proven to be highly stable in chemical and biological environments and have demonstrated excellent potencies in-vitro and in-vivo. IntoCell has also developed proprietary benzodiazepine dimers and modified duocarmycinoids that show high potency with improved safety in preclinical models. IntoCell has created an OHPAS Linker-toxin Library containing a variety of toxins that can be optimized for the fast delivery of a pre-clinical candidate in novel ADC programs.

Using its novel chemistries, IntoCell is developing a pipeline of proprietary ADCs that includes a B7-H3 programme which is demonstrating excellent preclinical data.

For more information, please visit http://www.intocell.co.kr

PharmaVentures acts as independent commercial expert with respect to Spectral MD’s IPO listing this month on London’s AIM

Oxford, UK, 29 June 2021

PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert with respect to Spectral MD’s listing on London’s AIM on June 22nd.

Adrian Dawkes, Managing Director at PharmaVentures, said: “Through our expert knowledge across the medical device sector, and in particular the wound care market, we were pleased to be able to provide an independent expert assessment of Spectral’s DeepView® Wound Imaging System with respect to their Initial Public Offering (IPO) on AIM.”

Fintan Walton, Chief Executive of PharmaVentures, said: “Providing independent expert commercial and technical insight in healthcare is a key component in contributing to understanding investment opportunities including IPOs and other transactions. PharmaVentures has a long and strong history in providing valuable commercial insight to our clients because of our deep commercial knowledge of the healthcare sector.”

Marc Dudek, Director of Business and Corporate Development at Spectral MD, said: “Spectral MD is delighted to IPO on the AIM market. This funding will be used to support further development of our diabetic foot ulcer application and to initiate our expansion into the UK and EU markets. We believe our differentiated technology has the potential to improve the standard of care for victims suffering from burn wounds and diabetic foot ulcers.”

PharmaVentures has a strong track record for writing Independent Expert Reports for companies listing on public markets such as AIM. These reports assist both the lay person and those with industry experience to understand how the company’s particular technology is positioned against competitors, where it brings technical or clinical benefits and how that relates to commercialisation.

– Ends –

For further information, contact:

Lisa Holloway
Senior Marketing Manager
PharmaVentures Ltd
+44 (0) 1865 332 700
enquiries@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 29 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, and fundraising)

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

For more details, visit https://www.pharmaventures.com

About Spectral MD                                                        

Spectral MD develops technology using predictive analytics and AI algorithms to help clinicians make more accurate and faster treatment decisions. There are no diagnostic imaging devices that provide clinicians with an objective and immediate assessment of a wound’s healing potential.

Spectral MD’s DeepView® Technology provides an informed solution for clinicians and allows for a clear picture of the wound to be established prior to treatment or other interventions.

www.spectralmd.com

NOTE: This Press release is issued by PharmaVentures Capital Limited which is authorised and regulated by the Financial Conduct Authority (FCA), and is for information purposes only. This communication does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.